MedPlus Health Services Limited Fundamental Analysis (NSE: MEDPLUS.NS)
MedPlus Health Services Limited Fundamental Analysis (NSE: MEDPLUS.NS)
MedPlus Health Services Limited (NSE: MEDPLUS.NS) shows weak financial fundamentals with a PE ratio of 39.29, profit margin of 2.91%, and ROE of 11.02%. The company generates $72.3B in annual revenue with moderate year-over-year growth of 9.09%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 57.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze MEDPLUS.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakMEDPLUS.NS struggles to generate sufficient returns from assets.
Valuation Score
WeakMEDPLUS.NS trades at a premium to fair value.
Growth Score
ModerateMEDPLUS.NS shows steady but slowing expansion.
Financial Health Score
ModerateMEDPLUS.NS shows balanced financial health with some risks.
Profitability Score
WeakMEDPLUS.NS struggles to sustain strong margins.
Key Financial Metrics
Is MEDPLUS.NS Expensive or Cheap?
P/E Ratio
MEDPLUS.NS trades at 39.29 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, MEDPLUS.NS's PEG of 2.23 indicates potential overvaluation.
Price to Book
The market values MedPlus Health Services Limited at 4.19 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 12.08 times EBITDA. This signals the market has high growth expectations.
How Well Does MEDPLUS.NS Make Money?
Net Profit Margin
For every $100 in sales, MedPlus Health Services Limited keeps $2.91 as profit after all expenses.
Operating Margin
Core operations generate 4.35 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.02 in profit for every $100 of shareholder equity.
ROA
MedPlus Health Services Limited generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
MedPlus Health Services Limited generates limited operating cash flow of $3.13B, signaling weaker underlying cash strength.
Free Cash Flow
MedPlus Health Services Limited produces free cash flow of $2.71B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $22.53 in free cash annually.
FCF Yield
MEDPLUS.NS converts 3.27% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
39.29
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.23
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.19
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.15
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How MEDPLUS.NS Stacks Against Its Sector Peers
| Metric | MEDPLUS.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 39.29 | 31.61 | Worse (Expensive) |
| ROE | 11.02% | 541.00% | Weak |
| Net Margin | 2.91% | 30180.00% | Weak |
| Debt/Equity | 0.00 | 0.54 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 5.70 | Weak Liquidity |
| ROA | 0.00% | -8.00% (disorted) | Weak |
MEDPLUS.NS outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews MedPlus Health Services Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
92.13%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
6098.05%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
7663.07%
Industry Style: Defensive, Growth, Innovation
High Growth